Teleflex Incorporated (TFX) Earnings Call Transcript & Summary
October 27, 2022
Earnings Call Speaker Segments
Larry Keusch
executiveHello, everybody, and thank you for joining us on this Teleflex Incorporated call covering results for the third quarter of 2022. You can find the slides and press release that go with today's discussion on our site, teleflex.com. Just to note, a replay of this call will be posted on our website as well. For information about how to listen to that replay, please check this morning's press release. On the line with us today are Liam Kelly, our Chairman, President and Chief Executive Officer, along with Thomas Powell, Vice President and Chief Financial Officer. Liam and Tom are going to deliver prepared remarks, after which we'll take your questions. Prior to starting, I want to point out that certain topics we cover on this conference call will include forward-looking statements about future events, which are described in our slides. We caution that these statements are forward-looking by nature, carrying risks and uncertainties, so actual events or results could differ materially. Among the factors that might cause actual results or events to differ materially are those noted in today's press release and in our SEC filings, such as our Form 10-K, which you can find on our website. Throughout this conference call, management will be making statements about intra-quarter business performance. This commentary is being provided so the investment community gains additional insights into trends, and these disclosures might not be given in later quarters. Having said that, I'll hand the call over to Liam now for his remarks.
Liam Kelly
executiveThank you, Larry, and good morning to all of you. In the third quarter, Teleflex brought in revenues of $686.8 million, which represents a 1.9% decrease from a year earlier on a reported basis, and a 2.4% increase in constant currency terms. Versus the same period last year, revenue tied to the manufacturing and supply transition agreement connected to our earlier divestiture of the Respiratory assets dragged growth down by 1.3% during the quarter, which means underlying constant currency growth came to 3.7%. Adjusted earnings per share fell 6.8% compared to a year ago, landing at $3.27. As we look at the quarter, most of our business units performed well. If you set aside UroLift and make an adjustment for the Respiratory divestiture, the other 88% of the business delivered an underlying growth rate of 4.3% in the third quarter. This strong showing keeps demonstrating the advantage of Teleflex's diversified portfolio, which was deliberately assembled to focus on treating critically ill patients. Revenues improved as the third quarter went on, with September coming in stronger than July and August. Our OEM business unit produced double-digit constant currency revenue growth versus a year ago. Meanwhile, the Interventional business unit expanded by roughly 9%. Another solid result came from our Surgical business, which posted mid-single-digit constant currency growth compared with a year earlier. Geographically speaking, we achieved strong results in Asia, which remains a key growth engine for Teleflex. On the other hand, Interventional Urology is still dealing with patient flows to urologists that continue to be lower than a year ago, along with staffing shortages, and third quarter revenues came in slightly below internal targets. During the quarter, our high-growth revenue, which encompasses UroLift, MANTA, hemostatic products, EZ-IO, on controls and PIC, sustained momentum across most growth drivers. Over the 9 months, UroLift has fallen 5.8% versus a year earlier. Meanwhile, the rest of the products in the high-growth portfolio keep delivering healthy gains, with 14% growth. Now shifting to durable core revenues, which made up more than 60% of revenues in 2021. During the first 9 months of 2022, the durable core has produced 4.6% growth relative to the same period last year. Now on to inflation. Certain elements showed stabilization in the quarter, with some areas getting better. Specifically, sea freight costs came down consistent with what we had expected internally; we still witnessed elements of elevated supply-chain disruption throughout the third quarter. The availability of certain raw materials and components has not yet returned to normal. This situation led to backorder levels during the third quarter that were higher than anticipated, particularly in our Vascular and Interventional businesses. As we look forward, we expect some of those surprise back orders to clear out before 2022 comes to a close. Now, let's dig into the revenue numbers for our third quarter. I'll begin with a review of the revenues for our reportable segments in Q3. Unless I note otherwise, all growth rates I cite are in constant currency. In the Americas, revenue came to $405.1 million, down 2.7% versus the same period last year, which was a tough comparison. Revenue tied to the manufacturing supply-and-transition agreement related to our prior divestiture of the Respiratory assets pulled Americas growth down by 2.1%, implying that underlying performance was about flat for the quarter. Interventional delivered high single-digit expansion. However, declines in Vascular and Interventional Urology counterbalanced that. Additionally, during the third quarter, we encountered certain supply-chain interruptions. EMEA brought in $128.4 million in revenues, representing a 3.4% rise compared to the same period last year. From our perspective, procedure volumes keep getting better year-over-year. Now let's turn to Asia. There, revenues hit $82 million, which is a solid 20.5% year-over-year gain. Across the whole region, momentum was clear, as each geography achieved growth during the third quarter. China put up an exceptionally strong result, surpassing 19% growth. Now let's talk about our third quarter revenues broken down by global product category. Consistent with what I said previously regarding our reportable segments, when discussing how product categories grew globally in Q3, I'll use constant currency figures and order them according to the size of each business unit. Starting with Vascular Access: revenue dropped 0.8%, landing at $167.1 million. Part of what drove this quarter's results was a tough comparison stemming from fewer COVID patients in U.S. intensive care units compared with the prior year. As I noted earlier, backorders increased modestly over the quarter due to shortages of raw materials. Worth highlighting is that among our businesses, the vascular one has the greatest exposure to tieback packaging used in our kits and trays. We anticipate that tieback supply constraints will lessen during 2023 as additional industry supply comes online. We remain confident that our leadership position in the market for central venous catheters and midlines, along with our new coated PICC lineup, continues to set us up for dependable growth. Now turning to Interventional. We brought in $108.7 million in revenue, which is 8.9% higher than the same period last year. Our diversified portfolio turned in strong performance during the third quarter, as balloon pumps on control, MANTA, and complex catheters each contributed to growth. From where we sit, certain supply-chain disruptions continued to be felt throughout the quarter. Switching over to anesthesia. Revenue came in at $97.6 million, representing a 5.8% increase year-over-year. This business was up against a tough comparison, given the 26.6% growth it posted last year. Within our bigger franchises, regional anesthesia, hemostatic products, and endotracheal tubes each posted double-digit growth in the third quarter. Turning to our Surgical segment, we brought in $93.1 million, which was another strong showing and amounted to 6.2% growth compared with the same period last year. Looking at our biggest product categories, skin stapling posted the strongest growth this quarter, and metal and polymer ligation clips saw their growth pick up pace from one quarter to the next, following the COVID-driven lockdowns in China that occurred during the second quarter. It's worth pointing out that the third quarter's surgical figures contain no revenue at all from the Standard Bariatrics acquisition. Moving to Interventional Urology, we recorded $79 million in revenue, which was roughly flat sequentially, down 4.6% year-over-year, and came in a bit under what we had anticipated internally. The broader climate for elective BPH procedures still hasn't gotten back to where it normally is. According to third-party data, total patient visits to urologists fell by a high single-digit percentage compared with a year earlier during the quarter, and that has put pressure on the funnel for BPH procedures. On top of that, we're still up against a staffing constraint. Teleflex ran a survey of U.S. urologists back in August of this year, and out of 125 people who responded, 52% said they'd dealt with staffing problems. That same survey showed urologists working out of offices are seeing far more patient cancellations each week compared with those based in hospitals. OEM revenue rose 14.4% versus the prior year, reaching $71.3 million, even with a difficult comparison against last year. Our order book is still in a strong spot, since customers see the wide range of things we're capable of doing competitively — that includes rapidly expanding markets for thin wall interventional microcatheters used to assess small vessels, plus fine wire for sensing and ablation technology. In the third quarter, Other revenue came in at $69.9 million, down 9.9% from a year earlier. Most of that drop comes from reduced manufacturing and supply transition agreement revenue compared with last year. Our expectation is still that all MSA revenue will come to an end once 2023 is over. That wraps up what I wanted to say about third quarter revenue performance. Now moving to a few commercial and clinical updates: on September 28, we completed our purchase of Standard Bariatrics, paying $170 million upfront in cash, with as much as $130 million more contingent on hitting specific commercial milestones. Standard Bariatrics has brought the Titan SGS stapler to market — a novel powered stapling technology built specifically for sleeve gastrerectomy. We estimate 120,000 sleeve gastrectomy procedures took place in 2020.
Liam Kelly
executiveThere are several reasons why we're thrilled about bringing Standard Bariatrics into the fold. To start with, the Titan stapler tackles unmet needs in sleeve gastrectomy by giving surgeons the longest continuous push and staple line available at 23 centimeters; its design is meant to help surgeons achieve a more consistent and symmetrical sleep pouch anatomy, which sets their patients up for optimized outcomes. Every patient's anatomy differs, of course, but because the Titan's staple line is so long, surgeons can plan and place staples in 1 firing, which minimizes the variations that sometimes come with using multiple overlapping short cartridge staple firing. Beyond that, the design could yield a staple line that is more secure, with reduced likelihood of leaks, which higher burst pressures demonstrate. Next, in the sleep gastrectomy market, we think we can compete effectively for stapling share. Following a U.S. launch in the third quarter of 2020, we anticipate Titan stapler revenues will reach roughly $15 million by 2022. With the Titan stapler now part of the Teleflex surgical portfolio, we expect that momentum will keep building. The Titan Stapler products <<inaudible>> align with the bariatric surgery call point we already have in our Surgical business and work alongside our ligation clip portfolio, MiniLap percutaneous surgical system and Weck EFx special closure portfolio. On top of that, bringing the Standard Bariatrics sales team on board made our commercial organization serving the sleeve gastrectomy market twice as large; as demand increases, we can scale up further using existing Teleflex representatives, and doing so would expand the stand-alone sales force of Standard Bariatrics by more than three times. Last, we foresee a route through value analysis committees involving a carve-out, thanks to how differentiated the stapler is, and that makes us confident we can grow our user base in the years ahead. Number three, purchasing the Titan Stapler aligns with Teleflex's approach of putting money into novel products and technologies capable of delivering meaningful gains in clinical efficacy, patient safety and comfort, cutting complications, and bringing down the total cost of care. Looking at the numbers, this deal gives Teleflex's long-term revenue growth profile an immediate boost and, as time goes on, will lift both our gross margin and our operating margin. Now turning to Interventional. We brought the Langston Dual Lumen Catheter back to market, and we anticipate sales will build through the fourth quarter and on into 2023. Also, during the TCT conference in mid-September, we put a spotlight on the Karolinska 1000 consecutive MANTA device study. Teleflex did not sponsor this study, and it stands as the biggest real-world assessment of the MANTA device among patients going through TAVI. What the study showed was complication rates that were low along with a learning curve that was short. To be more specific, major vascular complications tied to the MANTA device showed up in 4.2% of patients, a figure in line with both the SAFE MANTA IDE study and the MARVEL prospective registry. Turning to our market development goals for UroLift, we once again felt good about how the quarter went. We kept training new physicians through the third quarter, and we remain on pace to hit our target for the year. Because surgeons now have greater access, we recently ran a live BPH Summit training event in the U.S., continuing our outreach to doctors who have not yet received UroLift training. In addition, we look forward to a BPH Summit coming up in Japan during Q4. Surgeons continue to give really positive feedback on UroLift 2, and during Q3 there was stronger momentum for UroLift advanced tissue control for obstructive median lobes. Newly published data in the peer-reviewed Journal of Endourology demonstrated that in a controlled clinical trial of the UroLift system for obstructive median lobes, during the first 3 months of treatment men experienced greater symptom relief than patients who received placebo and TURP in other controlled studies. Encouragingly, those patients did not experience high-grade serious adverse events. The data also indicates that for obstructive median lobes patients, symptoms and EuroFlow outcomes were largely the same whether treatment happened in controlled or real-world settings. Our thinking is that if we bring UroLift 2 to market in advanced tissue control, we'll be able to deepen our relationships with surgeons and drive usage further into the indications covered by our label. Because of what we accomplished as Q3 came to a close, we remain on schedule to move the great majority of our U.S. customers to UroLift 2 before 2022 ends; turning now to how our international expansion strategy for UroLift is progressing. We have entered the opening stages of a multiyear effort to expand across multiple geographies internationally, and that ought to serve as a significant growth driver in the years ahead. Momentum from the UroLift launch in Japan, which got underway on April 1, continues to grow, and it is performing in line with our plan. The number of cases continues to climb, and what we've seen from those results has us quite optimistic. As we look forward, there's real excitement about bringing our virtual reality offerings to market, which should strengthen how we train physicians and how our sales force interacts. Based on what we've achieved up to now, we believe we'll be in a strong spot to build further momentum during 2023 as we extend our footprint into important areas across the country. Turning to our other markets outside the U.S.; the commercial milestones we've set for UroLift remain on schedule. In China, our first launch efforts get underway in Q4, concentrating on major cities and working with the urological society to drive adoption. Beyond that, our expectation for Q4 still includes reimbursement being updated in France, plus launches across certain areas of Italy and Spain. Turning to another matter: those of you who follow Teleflex will recall our July 2020 announcement to the investment community that a Civil False Claims Act investigation had been opened by the Department of Justice concerning NeoTract Inc., one of our subsidiaries. I'm happy to report that the U.S. Department of Justice let us know in August 2022 that this investigation had been closed. With that matter now resolved, we're glad, and we look forward to keeping our attention on the patients we serve worldwide each day. That's everything I had prepared to discuss. At this point, I'd like to hand things off to Tom, who will walk us through the financial results for our third quarter in greater detail. Tom?
Tom Powell
executiveThank you, Liam, and good morning. Given that we've already gone over how the business did on revenue, I'll begin with margins. For the quarter, adjusted gross margin was 58.7%, an 80-basis point decline versus the equivalent period last year. The year-over-year fall came about because of the incremental inflation we had expected, partly offset by favorable pricing. As anticipated, sea freight has gotten better, although raw materials and component availability has yet to normalize. Notably, our pricing strategy kept building momentum across the third quarter. Adjusted operating margin in the third quarter was 26.9%. That 160-basis point decrease compared with a year ago stemmed from a thinner gross margin, expense deleverage related to lower revenue versus last year, cost inflation including wages, and intentional investment in the business to drive our growth drivers — partly offset by disciplined control of expenses that don't generate revenue. Net interest expense for the third quarter was $13.2 million, versus $11.8 million a year earlier. That $1.4 million rise over the prior year reflects net interest expense facing higher rates than last year, partly offset by lower average debt outstanding. For the third quarter of 2022, our adjusted tax rate was 9.8%, compared with 11.3% a year earlier. Looking at our adjusted tax rate, the decline versus last year is largely due to our continued efforts to make our global structure more tax-efficient. That said, some tax expense went against us, stemming from the new U.S. tax law provision requiring certain R&D expenses to be capitalized. Turning to the bottom line, adjusted earnings per share for the third quarter was $3.27, which is 6.8% below the equivalent period last year. Let me now shift to a few balance sheet and cash flow highlights. Across the 9 months, cash flow from operations was $244.4 million, while in the prior year period it was $450.5 million. This decrease largely stemmed from weaker operating results, bigger tax outlays, larger payments tied to payroll and benefits, plus negative working capital shifts. Those shifts resulted from us purchasing more inventory so we could keep service levels high for customers while global supply chains remained unusually unstable. Now turning to the balance sheet. Our financial position remains solid. At the close of the third quarter, we held $397.3 million in cash, versus $445.1 million at the close of 2021. The lower cash total reflects $144 million in payments toward our senior credit facility. By the close of Q3, 42% of our outstanding debt carried a floating rate, and we ended the quarter with net leverage around 1.7x. Including Standard Bariatrics on a pro forma basis, that net leverage figure comes to 1.9x — still comfortably under the 4.5x covenant. Switching now to the update on our 2022 guidance. Our constant currency revenue growth outlook for 2022 remains at 3.25% to 4.25%. If you take out what the Respiratory divestiture contributed and account for the one shipping day we lost, the underlying growth outlook for the business is still north of 5% year-over-year at the midpoint of that 2022 constant currency revenue growth guidance range. That would give you an average for the year of approximately 1.05 to the euro. Let's turn now to the topic of currency exchange. Compared with what we communicated to you previously, the US dollar has strengthened further against a broad range of currencies. As we see it right now, currency movements will produce a drag on revenue of about 4% in 2022, versus the 3.7% we had anticipated earlier. In dollar terms, that amounts to roughly $110 million of reported revenue headwind versus the prior year, an increase from approximately $100 million under the earlier outlook. With this updated currency picture factored in, we are lowering our reported revenue growth to a range of negative 0.75% to positive 0.25% for 2022, equivalent to between $2.789 billion and $2.817 billion. Now for a few additional points on the 2022 revenue outlook. We expect Standard Bariatrics to contribute an extra $4 million to $5 million in revenue in Q4. On UroLift, our current model for 2022 puts revenue at roughly $320 million, below the $335 million we had previously told you to expect. When we issued that earlier guidance, we had assumed UroLift's situation would improve as 2022 progressed, with revenue rising quarter over quarter in both Q3 and Q4. Because headwinds in the procedure environment have persisted, our revised guidance now assumes things won't get better underneath in the current climate for the rest of the year. Let's move on now to the middle of the income statement. Looking ahead to 2022, we're projecting gross margin between 58.75% and 59.25%, down from our earlier estimate of 59% to 59.5%. This lower forecast reflects an unfavorable mix. Our gross margin guidance still factors in additional inflationary pressure, creating a roughly 100 basis point headwind compared to last year. The key point is that we remain confident in achieving at least 50 basis points of pricing this year, which will help offset some of the inflation affecting our cost of goods in 2022. As always, we'll continue to review our global pricing and make adjustments as opportunities arise. For operating margin, we now expect a range of 26.5% to 27%, compared to 26.75% to 27.25% previously. The outlook we're providing now factors in both the gross margin impact and the added operating costs that come with Standard Bariatrics — those weren't reflected in our prior guidance. Partially balancing that out is operating expense in the third quarter that came in better than we had expected. Turning to the items below the line: for 2022, we continue to expect an adjusted tax rate of 11% to 11.5%. As for net interest expense, the 2022 figure is now projected at roughly $54 million, up from the $51 million we previously anticipated. Most of that increase in what we now expect to pay out for net interest comes from borrowing tied to buying Standard Bariatrics. Now onto earnings: we're trimming our adjusted EPS outlook for 2022 to $12.80 to $13.20, versus the prior $13 to $13.40 range. Several things feed into this revised view: our third-quarter results, partly offset by dilution from the Standard Bariatrics deal, foreign exchange shifts, and margin strain related to product mix. On this new guidance, adjusted earnings per share between $12.80 and $13.20 works out to a 4% decline versus a year ago at the bottom of the range, and 1% lower at the top. Once you set aside extra inflation, currency effects, the divestiture of our Respiratory business, and the drag from folding Standard Bariatrics in, the remainder points to core adjusted EPS growth, at the midpoint of our guidance, running at a high single-digit rate compared with the same stretch of 2022. That would give you an average for the year of approximately 1.05 to the euro. It further shows how our portfolio of growth drivers delivers and our capacity to expand profits amid a stretch of significant macroeconomic challenges. That wraps up my prepared remarks. I'll hand things over now to Liam for some closing thoughts.
Liam Kelly
executiveThank you, Tom. To wrap up, I want to emphasize 3 main points regarding the third quarter and what we expect for 2022. To begin, the results we posted for Q3 show how the Teleflex portfolio has been diversified, thanks to a blend of our growth drivers and the steadiness of durable core revenues. Crucially, we will keep prioritizing spending on our future growth drivers, all while keeping overall business costs in check. Next, during the quarter, we strengthened our growth drivers by acquiring the Standard Bariatrics Titan SGS powered stapler. As we successfully bring Standard Bariatrics into the Teleflex Surgical business and broaden the footprint of this novel stapling technology, we anticipate revenue growth and margin accretion over time. For that reason, we foresee that this acquisition of Standard Bariatrics will boost our long-term constant currency growth. Lastly, we are still carrying out our long-term growth strategy. We will keep investing incrementally in our high-growth portfolio and generating reliable expansion within our durable core portfolio. We have levers ready to produce additional margin expansion. Also, our balance sheet remains strong, with pro forma leverage at 1.9x, which gives us substantial financial flexibility for our capital allocation priorities, M&A included; that brings my prepared remarks to a close. At this point, I'd like to hand the call back to the operator for Q&A.
Cecilia Furlong
analystLiam, I'd like to begin with what you said about UroLift, specifically the site of care you mentioned — where patient flow is going, offices versus inpatient. Could you describe how that has moved compared with pre-COVID times? And then the part DTC plays — you brought up surgeon training. What's your thinking on DTC from here?
Liam Kelly
executiveCecilia, thanks for asking. On the topic of patient flow before COVID and after it: we know Q2 saw patient flow fall roughly 12%. During Q3 it dropped in the high single digits, and we also know that in 2021, patient visits stayed under pre-COVID levels. Put those together, and what we're looking at is a substantial decline in patient flow versus pre-COVID. Staffing shortages are the other obvious factor. Now across the remainder of our business, and that includes the UroLift portfolio as well, staffing levels did improve modestly on the hospital side of service. So during the quarter that was somewhat encouraging. And should that keep going — it will remain encouraging. As for our DTC, our belief is that DTC keeps adding value. We're exceeding our targets when it comes to patients being transferred to urologists. In fact, TV is the dominant way men initially hear about UroLift. So it's certainly a medium we intend to keep using. And awareness of the UroLift brand keeps climbing. It now sits at 19%, far ahead of TURP on that measure, and TURP is viewed as the gold standard where brand awareness is concerned, which is why I'm using TURP as the comparison. So the results from DTC have us very encouraged. And our expectation is to carry on with it. Our belief is that the market will recover in time. Our belief is that patient flow will get better. Our belief is that staffing levels will get better. And once that happens, we're well positioned to capitalize on it.
Cecilia Furlong
analystExcellent. If I may ask a second question, I'd like your thoughts on Japan too — that first market introduction. Could you walk us through your own input, what results you've observed so far, and how you see the fourth quarter shaping up? Then, looking past 2022, how confident are you — particularly considering the present macroeconomic conditions — in that 15% expansion figure you presented during the Analyst Day earlier in the year?
Liam Kelly
executiveYes, of course. Japan's developments give us reason for optimism. You're aware that during Q2 I traveled there and spoke with several urologists. Within that country, uptake remains quite robust. Clearly, in this quarter we'll perform our inaugural UroLift procedures in China, which represents another solid opportunity for the company. Regarding the LRP, naturally we must witness the market bounce back; and I assume your question concerns UroLift specifically — I believe the LRP showed a 15% CAGR for UroLift across that 3-year span. Our LRP actually doesn't start for another 2-and-a-bit months. The approach used 2020 as the base, then 2022 as a base, with 2023 serving as the initial year. As I've mentioned, we must observe end markets bouncing back; we must observe patient flows starting to return. We also must observe staffing levels getting better. We stand ready for when that occurs. Our sales force has no vacancies. The DTC has carried on. The clinical data is persuasive. The market remains enormous. In the United States, 12 million men still struggle with BPH. Our patient survey, which we conducted, indicates we're experiencing an elevated volume of cancellations among patients for BPH procedures. As conditions keep getting better, we'd anticipate that improving as well.
Jayson Bedford
analystPerhaps this one is for Tom or the team. In the current climate, the top line has decelerated somewhat. I'm curious whether that has changed how you view the speed of margin improvement, particularly with respect to your LRP targets.
Tom Powell
executiveWell, what I'd say is that when revenue decelerates, you inevitably give up leverage in the P&L. To keep pushing margin expansion, we need to see that top line advancing. As Liam just mentioned, the LRP is still a couple of months away from kicking off; and we expect to keep growing the top line. We'll need to watch how inflation affects us, and that has definitely been a headwind too; but when you look at the business, the core pillars of margin expansion are intact, with restructuring programs continuing. We are seeing solid growth in our high-growth portfolio, which, as you're aware, carries a margin above the average. So as Liam said, restoring UroLift and expanding in North America at a healthy rate will definitely help us ensure that margin delivery across the longer-term horizon.
Liam Kelly
executiveAnd Jayson, one more thing I'd mention — you're right, revenue growth has decelerated. However, once you adjust for the days tied to the Respiratory divestiture and use the midpoint of the guidance we gave for the rest of the year, the math shows our underlying growth actually exceeds 5%. And that holds true even with the downturn we're seeing right now in UroLift revenue. Clearly, if that improves, it works in our favor. As you're aware, our pricing discipline is really strong. And we believe we'll outperform that 50 basis points figure we set out by a wide margin. On top of that, we have restructuring programs that, over the LRP, will generate an additional $28 million of benefit flowing through the gross margin line down to operating margins. So there are many moving parts, we're operating in an inflationary climate, and this year we might give up some leverage. Still, if conditions get better, we'll find out what unfolds across the LRP timeframe.
Jayson Bedford
analystAlright, and a brief follow-up question. Liam, you brought up a backlog that was higher than usual in the quarter. Could you put a dollar figure on what drove that?
Liam Kelly
executiveI'd rather not dive too deep into exact dollar figures, but obviously it's clearly in the millions, and the effect fell really on the Vascular Access business along with the Interventional Access business; those 2 took the biggest hit. In both of those businesses we rely on outside suppliers, 1 being Tyvek and the other an external extrusion company, which is giving us some trouble right now. We'd anticipate that settling down during the fourth quarter, and that's partly why we can hold our constant currency guidance, along with bringing Standard Bariatrics into the fold.
Shagun Singh Chadha
analystIs my audio coming through clearly?
Liam Kelly
executiveYes, Shagun, we're able to hear you.
Shagun Singh Chadha
analystI was curious, Liam, whether you might provide particular figures indicating that patients will come back once conditions settle down. Given how quickly UroLift cancellations have been happening, I find that somewhat unexpected. So why are you optimistic? Also, your Q4 UroLift outlook now suggests $86 million, whereas the earlier forecast pointed to $101 million. What reassures you that the 15% CAGR can be reached in '23 and afterward? Also, could you restate your assurance regarding the 6% to 7% LRP should UroLift decelerate in 2023 and later? I realize your purchase of Standard Bariatrics contributes roughly 60 basis points, which ought to counterbalance part of that pressure. Still, please discuss the 6% to 7% figure, and your approach to M&A when considering the portfolio as a whole.
Liam Kelly
executiveAll right. Thank you, Shagun. That contains plenty to address. Let me start. Like I mentioned before, the LRP kicks off in 2-and-a-bit months, I believe I remain confident about the 6% to 7% we set out, and bringing in Standard Bariatrics strengthens my assurance regarding the 6% to 7% CAGR throughout that span. Once more, I would remind everyone that the 15% figure for UroLift is likewise a CAGR. And within the first year of that 3-year plan, we likely face a simpler comparison, which ought to assist us in enhancing it. Why am I confident patients will come back? Since their numbers are large. Our target market consists of the 1.5 million men who have BPH, took the pill and stopped taking it, out of 12 million patients. I also take encouragement from what is occurring in the hospital setting, where staffing numbers are beginning to get better. Based on what our patient study taught us, certain patients struggle to arrange appointments so they can actually visit the urologists; therefore, should that staffing gain in hospitals extend to the office and the ASC, that ought to further help bring that back. Your calculation is right — it would mean for Q4 a figure of $86 million for UroLift. What is factored into that is simply the usual seasonality one observes from the deductible effect that occurs annually as we move from Q3 to Q4. And clearly, the contribution from international markets as we grow there; so within our $86 million, there is no implied ongoing recovery. Should that occur, it would be beneficial, yet our guide as issued today does not imply it.
Matt Taylor
analystIs the audio coming through clearly for you?
Liam Kelly
executiveYes, Matt, we're able to hear you.
Matt Taylor
analystThere are two things I'd like to ask about. Let me limit myself to <<inaudible>>. What I was hoping to hear more about is — you mentioned that you'll be comfortably above 50 basis points. Could you share any indication of just how much stronger the trend is looking? And beyond that, is this something you can sustain into next year? Do you see it as lasting, or would you call it largely a onetime thing?
Liam Kelly
executiveMy view is that carving out pricing, even when the environment isn't favorable for it, has always been something Teleflex can do. During the past several years, when pricing wasn't being achieved by any of the companies we consider peers, we consistently managed to carve out 10 or 20 basis points. This year, I believe we'll do in excess of 50 basis points. Through the first 3 quarters, Matt, we're tracking ahead of that. And at a minimum, I do think we'll be able to repeat that again next year. An inflationary environment is what we're living in. It's having an impact on us. Our customers are feeling that impact too; we're trying to walk that very fine line where we're being partners with our customers, but at the same time, recognizing that we are seeing inflation. As a result of what's being passed on to us from our customers, inflation is costing us 100 basis points in gross margin this year. And therefore, there must be a recognition that we must pass some of that on to our customers and in a thoughtful way and in a way that maintains that business relationship with the customer.
Matt Taylor
analystOkay, understood. Understood. And now I'd like to verify a few figures. I looked back at what was disclosed regarding the high-growth portfolio excluding UroLift, and my impression is that Q1 came in at roughly low double digits, Q2 exceeded 20%, and Q3 also appeared to be low double digits by comparison — is that right? Also, regarding that 14% year-to-date figure, what's your outlook for the high-growth portfolio in the periods ahead? And do the quarter-to-quarter swings simply reflect comps? Or is there another factor at play?
Liam Kelly
executiveNo, comps aren't what's driving the quarter-to-quarter movement. Honestly, Matt, the quarter-to-quarter variation comes from some backorder clearance, since we've encountered a handful of Tyvek-related problems in certain businesses of ours; it works its way through within 1 quarter, and that's really what — if you revisit the Q2 transcript, we described how we had worked through certain backorders. So comps aren't really the main factor. It's genuinely about when these backorders get cleared as we get past some of the supply-chain constraints. And your math is right that we expect it to be running at slightly above 14% ex UroLift across the first 3 quarters. And clearly, we expect to remain within that range for the rest of the year. So our high growth ex UroLift is doing well and matching expectations. And when UroLift turns around, that whole high-growth bucket ought to strengthen; and clearly, for those of you building your models, Standard Bariatrics is going to be part of the high-growth portfolio going forward.
Mike Polark
analystI've got a question about UroLift, and then another about Standard Bariatrics. Regarding UroLift, looking at just the move from 3Q to 4Q — I realize this has come up in a different form before — how much of the lift is baked in from OUS efforts accelerating as we head into 4Q? Could you break down that $7 million sequential increase? What portion of it would you attribute to the core U.S. business, and how much reflects OUS starting to add more meaningfully?
Liam Kelly
executiveSure. On that point, what typically happens with U.S. seasonality is you get a bump of roughly 7% to 10%, which is tied to the deductible effect. As for OUS, Japan especially has been building up gradually, and as we told investors, its size is 1/3 of the U.S., and our expectation was that it would build at 1/3 of the U.S. pace. In its first year, the U.S. business did $5 million, then $15 million, then $50 million, and it keeps going from there. So if you apply 1/3 of that, that's a reasonable benchmark for Japan. And to be fully candid, the contribution from China during the fourth quarter is quite small, so I wouldn't suggest factoring in much for that. We will perform cases; getting people into and out of the country is challenging, but we're encouraged about building through 2023, and China would represent more of a 2023 ramp than any 2022 impact.
Mike Polark
analystThat's useful. Then regarding Standard Bariatrics, you're steering toward $15 million for the product in 2024, its first complete year, and I believe $30 million to $35 million the following year — quite a robust climb. The market is substantial, and you've built a substantial earnout into the deal. So I'm wondering, what are the sellers dreaming of here? What kind of upside does that suggest? And should they hit that earn-out, what would it imply for the revenue run rate, and across what timeframe — has that been laid out?
Liam Kelly
executiveYeah, Mike, the way I'd put it is that Teleflex hands over the entire $130 million, nobody will be more pleased than me, since that would signal the business performed beyond what I'd have expected. When I examine this business, it's a distinctive technology. Looking at it, many technologies that capture share tend to represent evolution rather than revolution. This one genuinely belongs in that group. It sits squarely in the sleeve gastrectomy space that surgeons work in daily; it makes the procedure faster, you get fewer leaks, greater burst pressure once you finish. Overall, it's gaining traction quite quickly in the field. Several of the high-volume users have already taken up the technology, and for us a high-volume user means someone performing 10 sleeves each month; we're quite heartened by how it's progressing; but returning to your question, should we disburse that $130 million, Teleflex would be thrilled.
Craig Bijou
analystA few things regarding UroLift. Liam, I appreciate everything you said, but I want to dig into one specific point — my understanding is that you mentioned physician visits declined 12% year-over-year during Q2. In Q3, though, the decline is now in the high single digits. Yet your sales were essentially flat quarter to quarter, if we call it that. So I'd like to understand how those two things fit together. You also noted that hospital staffing conditions were improving. But when it comes to the office setting, did staffing get better from Q3 to Q2, or did it deteriorate? And beyond that, as we examine these figures sequentially from Q2 to Q3, could there be some kind of timing element between the visit and the procedure baked into them?
Liam Kelly
executiveCraig, let me take your final question first. There is absolutely a lag. A patient needs somewhere around 6 to 8 weeks to move through the funnel and actually get a procedure done. They have to arrive, be seen by the urologist. They have to complete their IPSS score; they have to undergo a cystoscope. After that, they have to be scheduled for a procedure. In August, we conducted our survey of urologists. We found that, generally speaking, 53% of them are dealing with staffing shortages. However, when you look at urologists on the office side of service, their staffing shortages are more severe. Within that group of urologists, 61% reported that they were dealing with staffing shortages. So I think — on the hospital side of service, I did observe an improvement. In terms of staffing level, the office was where it stood in Q2, with no meaningful improvement. That said, Craig, once the hospital side of service improves, capacity gets freed up for the office and ASC to improve — approve. So my expectation is that a lag will exist before that improvement reaches the other 2 sites of service, since the hospital is also using contract labor and isn't paying as much as it did a couple of quarters ago. All of these dynamics should ultimately help release some labor into the other sites of service, but a lag is certain; and as I mentioned before, once that occurs, Teleflex is positioned well to capitalize on it.
Craig Bijou
analystAll right. I appreciate that context, Liam. And my apologies for drilling down to this level of detail. However, you both noted that September's performance across the company came in above what we saw in July and August. So I'd like to focus perhaps specifically on UroLift. I'm aware that June proved to be a difficult month for UroLift, but could you share anything about how monthly sales for UroLift trended during the quarter?
Liam Kelly
executiveYes, of course; so as we anticipated, the vacation period had an effect on August, and we were aware that this would be the case; however, we did observe a rise in the day rate during September, which likewise matched expectations; so — and as I mentioned, we witnessed better staffing levels. So the increase in our day rate in September, as we emerged from the holiday period, gives us encouragement, and that serves as the foundation for our Q4 guidance.
Larry Biegelsen
analystPhil here, sitting in for Matt. Is the audio coming through okay for everyone?
Liam Kelly
executiveYes, Phil, we've got you.
Analyst
analystTo revisit UroLift once more — should we anticipate that the pace of trainings holds up through Q4 and on into 2023? Also, I realize the timing around visit recovery remains somewhat uncertain, but once visits do come back, are you looking for more of a step change? Or does it look like a gentler climb, with patients returning gradually?
Liam Kelly
executiveRegarding training, in Q3 it landed exactly where we thought it would. We're building back up toward the usual roughly 400 physicians we'd put through training in a typical year. So we remain on schedule there. That's encouraging for us, since it tells us physicians still have interest in the procedure. They're eager to adopt it. We're transitioning from the early adopter group to the fast follower group, and that's pretty encouraging. On visits, the initial milestone in my view, Phil, is reaching a flat year-over-year comparison. We've come through this year at minus 15, minus 12, minus high single digits. So flat has to come first, before we get back to the normal upward cadence. And even at flat year-over-year, we'd still sit under 2019 pre-COVID levels; so patient visits have a ways to go; and you're right. After patient flow begins returning, a lag should follow. And then momentum ought to start building once patients are back and seeing their urologists.
Analyst
analystOkay. To shift gears, congratulations on the Standard Bariatrics purchase. I'm wondering if you'd need additional pieces surrounding that asset, or do you believe it can function independently in its current form? Also, more broadly regarding M&A, what's your perspective given that valuations have fallen and considering your own leverage ratios?
Liam Kelly
executiveSure. Let me start with Standard Bariatrics — obviously, that's a fantastic acquisition for us. We already hold a significant call point with the bariatric surgeon. We offer our mini lap, our percutaneous surgical system; we offer the Weck EFx closure, and we offer our cold ligation products. We've already got that call point established. With Standard Bariatrics, we now have an opportunity to double our sales force in that call point, and also to double how many salespeople are selling the Titan SGS. Turning to M&A, on a pro forma basis, leverage sits at 1.9x, so we're in pretty solid shape. We're out in the marketplace actively searching for assets. Internally, the team did run some analysis on the Standard Bariatrics acquisition, because I take your question to mean: given where your stock is trading, should you pursue a share buyback? And the truth is, if you're a short-term holder of Teleflex, a staff buyback in the first year might be the better option. Yet for someone who's holding on for the long haul — absolutely, looking out across a horizon of two, three, four, five, or even six years — the return ends up being considerably stronger when Teleflex taps its balance sheet for M&A instead of repurchasing shares, and that holds true even given where our share price sits right now. So that analysis has been done by us. Our confidence is high that we can deliver an improved return to shareholders by keeping up the work of folding appealing M&A into the business, and by extending Teleflex's footprint further into fresh procedures that fit well with what we do. That will serve as our guiding principle moving forward, and it's precisely what we intend to carry out.
Analyst
analystThis is Vick, filling in for Larry. We've just got a couple of questions. Could you give us some kind of framework for 2023? I'm not looking for formal guidance, but anything you already know about — say, FX or inflation moving through the P&L — that you could offer preliminary thoughts on? Also, is there any reason you believe you won't land in that 6% to 7% range? Then I have one more question after that.
Liam Kelly
executiveAs far as what we know today that will move through the P&L next year: FX will clearly have an effect. When we put our plan together for this year, we took the euro against the dollar — our largest exposure — and in Q2 we set it at parity for the rest of the year. We have since revised that, and that was among the factors behind the $10 million call down on euro and other currencies shifting, since we reset that rate. That leaves you with an average for the year of roughly 105 per euro. Should it remain at parity or drop under parity, that's clearly going to be a headwind in the year ahead. Inflation is elevated, we're seeing that, but we had already incorporated step-up inflation into our LRP going forward. As for the first year — your 2023 question — we'll address that in February, when guidance for the LRP's first year will be provided. That said, as I mentioned a bit earlier, I remain highly confident about the 6% to 7% overall. And with Standard Bariatrics now included, my confidence in that 6% to 7% across the LRP horizon is even greater.
Analyst
analystGreat. And I just have one more question. Could you discuss how much MANTA has been adopted during the quarter? And what's your outlook for the remainder of this year and maybe the next one?
Liam Kelly
executiveSure. Regarding MANTA, adoption is largely within TAVR procedures, where roughly 75% to 80% of our procedures take place, and that remains a key area of emphasis for us. Looking ahead to next year, something we're genuinely enthusiastic about is a clinical study underway in addition to the Karolinska one I mentioned earlier on the call, and the Karolinska study was outstanding since it essentially demonstrates that MANTA's adoption curve moves very fast. And what's even more promising, the complication rate aligns closely with our initial study, the SAFE study. So that's quite encouraging. We now have another trial in progress that will assist with MANTA's positioning and the application of ultrasound Doppler to place the product, which ought to make it simpler for those surgeons to keep using the product; as for adoption, we observe the penetration level clearly continuing to climb. It's a market worth $200 million to $300 million, and we're at a very early stage of the adoption curve; so we don't see any reason that won't keep going over a multiyear period.
Anthony Petrone
analystSo Liam, perhaps just a small amount regarding Japan and China, specifically on the timing of physician training — urologist training — in those markets. What's your expectation for how that will go? In the U.S., you're running roughly 400 each quarter, right? Does that same rhythm really apply in those markets? And maybe your initial thinking on 2023 when you consider what Japan and China will contribute in UroLift. Then I have 1 follow-up.
Liam Kelly
executiveYes, Anthony, welcome back. Glad to have you back on the story. Just so we're clear, it's around 400 per year that we'll do in the United States, not per quarter. In Japan, we're at a very early stage. So basically, our focus is on a few large metro areas. Tokyo, clearly, is one of those. This quarter, we added some sales staff as we continue preparing for 2023. And again, I'm quite optimistic about the ramp at one-third the size of the U.S. market. So next year, that should come to roughly a third of around $15 million, which is what we'd expect out of Japan. As for China, our first case is happening this quarter. Naturally, we're starting in the private hospital segment. And again, we'll kick off in the big metro hubs. We'll start with Shanghai, Beijing and Guangzhou, then after that we'll branch out further. Before we say much more about the number of doctors we're able to add, I want those first training sessions in China to wrap up. That said, we've already pinpointed several key opinion leaders there, and as I mentioned, the training is scheduled to happen in Q4. Both opportunities have us enthusiastic. In my view, these are the markets capable of truly moving the needle for UroLift — they're sizable enough, and Japan already offers solid reimbursement. Once we've gained some momentum in China's private markets, we'll secure reimbursement there and place it into the regional tenders, though getting to that point will require a few years.
Anthony Petrone
analystGreat. Then perhaps a follow-up for Tom. When we consider inflation for the coming year, I believe there was previously a dollar figure we ought to keep in mind that would carry into next year. A few companies have provided that dollar figure. So I'm simply curious whether there's a refreshed perspective on how inflation carries in, next year? And regarding the restructuring programs and offsets, could you give some detail on possible offsets?
Tom Powell
executiveSure. Well, like we said during our prepared remarks, inflation is still present for us. When we consider its components, we're actually observing a bit of improvement in sea freight, and we had anticipated that throughout this year. And so we're seeing freight costs decline quarter-over-quarter. Materials, on the other hand, remain at elevated rates. We haven't yet seen that level off or come back to a normalized level. So we will keep expecting inflation in our numbers. And historically, we've always had some level of inflation. I'd say that this year, it was greater than typical; we will have some carrying into next year owing to simply how we capitalize our inventory and how that rolls off the balance sheet. But at the moment, we're not able to provide specific guidance for inflationary pressures for next year; now having said that, there are several offsets. We discussed pricing, and we were very successful this year in getting pricing out there to help offset a portion of the inflation pressures. Restructuring programs are — that are currently announced will also deliver a benefit in next year; and as we look out to the next couple of years, we expect to achieve about 0.5 point in margin expansion from restructuring just next year with a full point over the next couple of years; so there is a nice benefit from restructuring, from pricing. Underlying in our business, we still have a nice mix benefit that we're seeing come through from our high-growth portfolio, as mentioned. They grow at a faster rate and carry a higher margin; so that's an underlying mix benefit that we continue to see and expect to see for the number of years over the LRP; and as UroLift continues to recover, we'll expect to see more and more contribution from that business unit as well on the margin line. So again, we'll give specific numbers on inflation as we get to the guidance for 2023.
Richard Newitter
analystPerhaps — really, two things on UroLift, and sorry to keep going back to your left. I realize there's already plenty of attention on it, but in my view it matters a great deal for investors. You brought up the CAGR, and yes, it's admittedly from what could be a smaller base. What I'd like to know is this: for that 15% to be reached, even starting from that lower point, could you tell us the smallest amount that the U.S. piece would have to expand? Put differently, over the CAGR, must you return to U.S. growth in the double digits for that to happen? Or is there sufficient headroom that you wouldn't have to count on that, given the international side? Then I have 1 follow-up.
Liam Kelly
executiveWell, Rich, it's obvious that since the international base is so much smaller, the percentage increase internationally will be far bigger than in the U.S. So logically, that tells you that reaching a 15% CAGR means the U.S., simply by definition, will come in under that 15% on that basis. Even so, I remain of the view that given how many men are affected, the 12 million in the United States with BPH plus the 1.5 who have BPH and fall into the drug dropout group, I continue to think that expansion inside the U.S. is very much achievable for us as an organization. And as I've noted a few times during this call, our position is strong. Our sales force is at full staffing. We have DTC running. We've just resumed holding a BPH Summit. We held a live one. Typically that gives us a good inflection toward generating more interest; and there will be 1 in Japan during the fourth quarter, after which we'll hold a number of them again next year. So from where I sit, it looks like things are moving closer to normal, at least on that front, when it comes to access; and to address your question, the U.S. certainly doesn't need to expand at 15% for the CAGR to hit 15%.
Richard Newitter
analystAll right. Yeah, I was really only asking that since I need to return to double digits, if you're able to respond to it. Then my second thing regarding UroLift was, I simply want to confirm I grasp the staffing problems in the office environment. From what I understood, physicians usually book their UroLift cases across 1 or 2 surgical days. So I'm merely attempting to feel out how that could explain the composition of where UroLift's volumes are recovering? Is it more — you mean the larger volume accounts that perhaps perform far more UroLifts, so they simply cannot return to their — reach those demand levels since they're running operations on multiple days each week? Or what precisely am I failing to see if the office environment ought to be simpler regarding scheduling and handling patients?
Liam Kelly
executiveYeah, that's correct, Rich. It is simpler regarding scheduling, which is the reason urologists prefer performing the procedure in that setting, since they retain control over it. However, what you're failing to see, I believe, in how you're analyzing it, Rich, is all the things that occur prior to the appointment being booked; so the patient must arrive, must meet with the urologists. They need to complete an IPSS score card. They might conduct some extra diagnostics upon them so as to establish the bladder health of that patient; and afterward they will certainly perform cystoscope, and all of that demands labor. Each stage throughout the process demands labor. It isn't solely regarding the procedure in itself, it's regarding what occurs with patient flow as they progress toward reaching the procedure as the endpoint, and that is what's creating the impact. Like I mentioned, 61% of office-based urologists in our survey plainly stated they had staffing charges; and I was down south roughly — a bit more than a month ago, meeting with urologists, and every 1 of them brought up staffing shortages, every 1 of them.
Mike Matson
analystYeah. I believe there are 2 things I want to ask. I'll simply go ahead and put them to you both at this point. So to start with, regarding UroLift and the sales force, have there been any shifts, interruptions, or departures among that team? Did you bring on more people during this year? Then my second thing relates to Standard Bariatrics — I mean, the chance in the sleeve gastrectomy space and bariatrics is something I completely grasp, but is this kind of a platform technology that could let you provide a whole array of stapling offerings down the road, so you could sort of break into that duopoly market?
Liam Kelly
executiveWell, I'd say we currently have a number of products serving that call point. Clearly, this is a rapidly expanding market. It's a market set to keep expanding as all of us in society keep consuming more of the bad things. So for us, we view this as a chance to keep driving penetration in the bariatric market, and there are certain aligned technologies that might interest us as we move further into this. Teleflex finds this area interesting and always has, as I mentioned before — we have our cold ligation clips there; we have our facial closure there, and we have our mini lab that we — our sales force is present there. On the topic of turnover, similar to every medical device company, we saw elevated turnover during 2021 throughout Teleflex and in UroLift. At present, our sales force in the UroLift area is quite stable. As I sit here today, I believe we have roughly 4 or 5 unfilled territories across the business units. And we're quite confident that we're positioned well to be prepared for the — for the moment the market bounces back.
Mike Matson
analystAlright. Regarding that stapling topic, what I was really trying to ask is whether you'd consider providing staples usable in areas other than bariatrics — something like the wider surgical stapling space?
Liam Kelly
executiveMy apologies, Mike, I didn't catch that. In our general surgical line we do already offer staples, though those are skin staplers; and clearly, both our Hemo-lok and our Horizon are ligation clips, cold and metal respectively. So I don't really see us competing against the major players and challenging them, in broader stapling, Mike. The thing is — the reason we entered this particular space is that it's so differentiated. It makes the procedure faster. It delivers a better result for the patient and a better result for the physicians; so that's likely why we moved into this stapling segment.
Larry Keusch
executiveAppreciate that, Abrika, and thanks as well to each of you who took the time to be with us on today's call. That brings the Teleflex Inc. Third Quarter 2022 Earnings Conference Call to a close.
Operator
operatorWe appreciate your being here. That brings today's call to a close. Thanks for attending, and thanks for taking part. You're free to hang up now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Teleflex Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Teleflex Incorporated earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Teleflex Incorporated or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.